Article summary
A new data release from Enveric Biosciences is sharpening the scientific debate at the heart of psychedelic drug development: can therapeutic benefit be separated from hallucination at the receptor level? In results announced this morning, Enveric reported new mechanistic findings from proprietary bioluminescence resonance energy transfer, or BRET, assays evaluating its lead candidate, EB-003. The […] The post Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy appeared first on Microdose.
Continue to the original publication for the complete article.